GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
GoodRx Reports First Quarter 2025 Results
May 7, 2025 4:13 PM EDTFirst Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations
SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," GoodRx, or the Company), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025.
First Quarter 2025 Highlights
Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million;... More